Updates are available Correction dated 2026-02-04
Click to view Correction: https://doi.org/10.1186/s13063-026-09525-6
-
Authors
Schaefer, Franz https://orcid.org/0000-0001-7564-9937
Montini, Giovanni https://orcid.org/0000-0002-7350-4475
Kang, Hee Gyung
Walle, Johan Vande
Zaritsky, Joshua
Schreuder, Michiel F.
Litwin, Mieczyslaw
Scalise, Andrea
Scott, Helen
Potts, James
Iveli, Pablo
Breitenstein, Stefanie
Warady, Bradley A.
-
Funding
Funding for this research was provided by:
Bayer AG
Innovative Medicines Initiative 2 Joint Undertaking (777389)
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 5 December 2023
Accepted: 26 February 2024
First Online: 21 March 2024
Change Date: 4 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-026-09525-6
Declarations
:
: These studies will be conducted in accordance with the protocol and with the following:
: Not applicable.
: The authors wrote the article with the assistance of a medical writer funded by the sponsor. The sponsor was involved in the study design and the writing of the report.FS discloses consultant fees for Amgen, Bayer, GSK, Otsuka, and Roche, and advisory committee fees for Alnylam and Bayer. GM discloses advisory committee fees for Alynlam, Bayer, and Chiesi Farmaceutici. JVW discloses advisory committee and consultant fees from Bayer. MFS discloses consultant fees from Bayer and Travere Therapeutics. ML has nothing to disclose. JZ discloses speaker honoraria (including speakers’ bureau, symposia, and expert witness) for Alnylam, Horizon, and Natera, and advisory board fees for Bayer and Kaneka. AS, HS, JAP, PI, and SB are Bayer employees. BAW discloses consultant fees from Bayer, Amgen, Roche, and GSK.
